Journal of Clinical Oncology, Vol 21, Issue 1
(January), 2003: 66-68
© 2003 American Society for Clinical Oncology
Combining Capecitabine and Gemcitabine in Patients With Advanced Pancreatic Carcinoma: A Phase I/II Trial
Viviane Hess,
Marc Salzberg,
Markus Borner,
Rudolf Morant,
Arnaud D. Roth,
Christian Ludwig,
Richard Herrmann
From the University Hospitals of Basel, Berne, and Geneva; the Cantonal Hospital of St. Gallen; and the Hospital St. Clara-Basel, Switzerland.
Address reprint requests to Richard Herrmann, MD, University Hospital of Basel, Petersgraben 4, CH-4031 Basel, Switzerland; email: rherrmann{at}uhbs.ch.
Purpose: Preclinical studies indicate positive interactions between capecitabine, an oral fluorouracil precursor, and gemcitabine, the current standard treatment for advanced pancreatic carcinoma (APC). In this study, we investigated the addition of capecitabine to gemcitabine treatment for patients with APC.
Patients and Methods: This multicenter study included patients naïve to chemotherapy who had histologically or cytologically confirmed, nonresectable or metastatic pancreatic carcinoma. Gemcitabine was given at a fixed dose of 1,000 mg/m2 on days 1 and 8 of a 21-day cycle. Capecitabine was given in increasing doses orally bid for 14 days followed by a 1-week rest. The maximum-tolerated dose (MTD) was defined as one dose level below the dose causing dose-limiting toxicity (DLT) in  one third of a cohort of six patients. We included an additional 15 patients at the MTD.
Results: Thirty-six patients were included. DLT occurred at a dose of 800 mg/m2 bid of capecitabine and consisted of myelotoxicity and mucositis. Hand-foot syndrome was not observed, and other toxic effects were mild. Thus, in this regimen, the recommended dose of capecitabine is 650 mg/m2 bid. In 27 patients with measurable disease, we observed one complete and four partial remissions. In addition, significant drops (> 50% from baseline value) of the tumor marker CA 19–9 occurred in 14 of 24 assessable patients.
Conclusion: The combination of capecitabine and gemcitabine is well tolerated, with apparent efficacy in patients with APC. Therefore, it is currently being compared with gemcitabine monotherapy in a phase III study.
This study was supported by Roche Pharma Schweiz.
Presented in part at the 36th annual meeting of the American Society of Clinical Oncology, New Orleans, May 20–23, 2000.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
E. M. Ciruelos, J. Cortes, H. Cortes-Funes, J. I. Mayordomo, B. Bermejo, B. Ojeda, E. Garcia, C. A. Rodriguez, M. Munoz, P. Gomez, et al.
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)
Ann. Onc.,
November 25, 2009;
(2009)
mdp536v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Cunningham, I. Chau, D. D. Stocken, J. W. Valle, D. Smith, W. Steward, P. G. Harper, J. Dunn, C. Tudur-Smith, J. West, et al.
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
J. Clin. Oncol.,
November 20, 2009;
27(33):
5513 - 5518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Ghaneh, E Costello, and J P Neoptolemos
Biology and management of pancreatic cancer
Postgrad. Med. J.,
September 1, 2008;
84(995):
478 - 497.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Koeberle, P. Saletti, M. Borner, D. Gerber, D. Dietrich, C. B. Caspar, W. Mingrone, K. Beretta, F. Strasser, T. Ruhstaller, et al.
Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research
J. Clin. Oncol.,
August 1, 2008;
26(22):
3702 - 3708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Kulke, L. S. Blaszkowsky, D. P. Ryan, J. W. Clark, J. A. Meyerhardt, A. X. Zhu, P. C. Enzinger, E. L. Kwak, A. Muzikansky, C. Lawrence, et al.
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
J. Clin. Oncol.,
October 20, 2007;
25(30):
4787 - 4792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ghaneh, E. Costello, and J. P Neoptolemos
Biology and management of pancreatic cancer
Gut,
August 1, 2007;
56(8):
1134 - 1152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Welch and M. J. Moore
Combination Chemotherapy in Advanced Pancreatic Cancer: Time to Raise the White Flag?
J. Clin. Oncol.,
June 1, 2007;
25(16):
2159 - 2161.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Herrmann, G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schuller, P. Saletti, J. Bauer, A. Figer, B. Pestalozzi, et al.
Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
J. Clin. Oncol.,
June 1, 2007;
25(16):
2212 - 2217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Ko and M. A. Tempero
Treatment of Metastatic Pancreatic Cancer
J Natl Compr Canc Netw,
September 1, 2005;
3(5):
627 - 636.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. J. Knox, D. Hedley, A. Oza, R. Feld, L. L. Siu, E. Chen, M. Nematollahi, G. R. Pond, J. Zhang, and M. J. Moore
Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial
J. Clin. Oncol.,
April 1, 2005;
23(10):
2332 - 2338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Stathopoulos, K. Syrigos, A. Polyzos, G. Fountzilas, S. K. Rigatos, N. Ziras, A. Potamiannou, I. Tsiakopoulos, N. Androulakis, G. Aravantinos, et al.
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study
Ann. Onc.,
February 1, 2004;
15(2):
224 - 229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
